Clouded in the murkiness of the debate surrounding the use of the PSA test is an increasing escalation of younger men (under the age of 50 years) being diagnosed with advanced prostate cancer. We know that there has been escalating incidence rate (IR) of prostate cancer PC noted in the last two decades. Many have [...]
It is known that Zoledronic acid (ZA) reduces the risk of developing skeletal-related events (SRE) which are caused by bone metastasis in prostate cancer (PCa). ZA also improves the quality of life (QOL). ZA has become a standard supportive therapy for men with prostate cancer who have bone metastasis. The big unknown is when should [...]
Last April there was some preliminary data from the long-term Phase II STAND study presented at 29th Annual European Association of Urology (EAU) Congress that showed that sipuleucel-T (Provenge) when given after the start of androgen deprivation therapy (ADT) seemed to enhance and sustain the immune response in men with a biochemical failure (PSA only) [...]
The vast majority of men with advanced prostate cancer will eventually develop bone metastases. Given this fact it is important to understand what is meant by the term bone metastases. Bones serve as the supporting framework of our bodies. Like the rest of us bones are constructed of cells. These cells compose a network or [...]
The following was written and posted by Paul Edwards to the Advanced Prostate Cancer Online Support Group: The March 2014 issue of the Asia-Pacific Journal of Clinical Oncology published an article “Why do some cancer patients receiving chemotherapy choose to take complementary and alternative medicines and what are the risks?” by authors from University of Queensland [...]